Inhibition of HSP90 Preserves Blood-Brain Barrier Integrity after Cortical Spreading Depression

Seph M Palomino1, Aidan A Levine1, Jared Wahl1

  • 1Department of Pharmacology, University of Arizona, 1501 N. Campbell Avenue, Tucson, AZ 85719, USA.

Pharmaceutics
|August 26, 2022
PubMed

Insights

Inhibiting heat shock protein 90 (HSP90) with 17-AAG prevents blood-brain barrier (BBB) leaks during cortical spreading depression (CSD). This finding suggests HSP90 inhibition as a potential therapy for headache disorders like migraine.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Cortical spreading depression (CSD) is implicated in headache disorders and increases blood-brain barrier (BBB) permeability.
  • Heat shock proteins (HSP) are suggested to maintain BBB integrity.
  • The specific role of HSP90 in CSD-associated BBB dysfunction requires investigation.

Purpose of the Study:

  • To investigate the role of HSP90 in blood-brain barrier (BBB) disruption during cortical spreading depression (CSD).
  • To evaluate the efficacy of HSP90 inhibition in mitigating CSD-induced BBB permeability.

Main Methods:

  • Utilized in vitro (bEnd.3 endothelial cell monolayer) and in vivo (Sprague Dawley rats) models.
  • Measured barrier integrity via transendothelial electrical resistance (TEER) and sucrose uptake assays.
  • Induced CSD using KCl application and inhibited HSP90 with 17-AAG.

Main Results:

  • HSP90 inhibition with 17-AAG prevented KCl-induced reduction in TEER and sucrose uptake in vitro.
  • 17-AAG pre-exposure significantly mitigated BBB leak in vivo following CSD induction.
  • Data demonstrate that inhibiting HSP90 reduces CSD-associated endothelial barrier leak.

Conclusions:

  • HSP90 inhibition effectively reduces blood-brain barrier permeability associated with cortical spreading depression.
  • Targeting HSP90 presents a novel therapeutic strategy for managing headache disorders, including migraine.